Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial
Source: View publication →
The EAGLES trial demonstrated that varenicline and bupropion do not significantly increase the risk of serious neuropsychiatric adverse events compared to nicotine patch or placebo, and confirmed varenicline as the most effective pharmacotherapy for smoking cessation.
Key Findings
Study Design
Study Limitations
Clinical Significance
The EAGLES trial provided definitive, high-quality evidence that first-line smoking cessation medications (varenicline and bupropion) are neuro-psychiatrically safe for patients with stable mental health conditions. By directly refuting earlier fears of drug-induced suicidality, the findings removed a major barrier to prescribing life-saving cessation therapies in psychiatric patients—a population that suffers disproportionately from tobacco-related morbidity and mortality. This led directly to the FDA removing the 'black box' warnings from both varenicline and bupropion.
Historical Context
Following early post-marketing case reports linking varenicline and bupropion to severe psychiatric adverse events—including depression, aggression, and suicidality—the FDA placed stringent 'black box' warnings on both medications in 2009. These warnings severely curtailed prescribing practices, particularly for patients with underlying psychiatric illnesses who paradoxically have the highest rates of smoking and the most urgent need for effective cessation aids. To definitively address this, the FDA and the European Medicines Agency (EMA) mandated an unprecedentedly large, rigorous safety trial. The resulting EAGLES trial decisively demonstrated the neuropsychiatric safety of these drugs, prompting the FDA to remove the black box warnings in December 2016.
Guided Discussion
High-yield insights from every perspective
Varenicline and bupropion are both effective for smoking cessation but operate via different mechanisms. How does varenicline's mechanism as a partial agonist at the alpha-4 beta-2 nicotinic acetylcholine receptor explain both its efficacy in reducing cravings and its ability to block the rewarding effects of smoking?
Key Response
Understanding partial agonism is a foundational pharmacology concept. Varenicline stimulates the receptor enough to prevent withdrawal and cravings (its partial agonist effect) but simultaneously blocks the binding of nicotine from a cigarette, preventing the massive dopamine spike that reinforces the smoking habit (its antagonist effect).
A 45-year-old patient with well-controlled major depressive disorder wants to quit smoking but is terrified to try varenicline because they read it causes suicidal thoughts. Based on the EAGLES trial, how should you counsel this patient and integrate this evidence into your shared decision-making regarding first-line therapy?
Key Response
Residents must translate evidence to patient counseling. The EAGLES trial explicitly demonstrated that varenicline does not increase the incidence of clinically significant neuropsychiatric adverse events compared to placebo or nicotine patch, even in patients with stable psychiatric conditions, allowing clinicians to confidently recommend it as a safe and highly efficacious first-line therapy.
While the EAGLES trial showed no significant difference in neuropsychiatric safety between treatments within the psychiatric cohort, the baseline rate of these events was inherently higher in this cohort compared to the non-psychiatric group. How should this nuanced finding influence the frequency and structure of follow-up for a patient with severe bipolar disorder initiated on varenicline?
Key Response
Fellows need to recognize that 'no difference vs placebo' does not mean 'zero risk.' Patients with underlying psychiatric illness have a higher baseline risk of psychiatric exacerbations (e.g., from nicotine withdrawal itself) and still require vigilant, structured psychiatric monitoring during cessation attempts regardless of the pharmacotherapy chosen.
The FDA originally placed a black box warning on varenicline based on post-marketing surveillance, which the EAGLES trial ultimately reversed. What does this reversal teach us about the limitations of spontaneous adverse event reporting systems compared to large-scale, actively controlled randomized trials when evaluating drugs for populations with high background rates of pathology?
Key Response
Attendings must contextualize evidence history. Post-marketing data is vulnerable to confounding by indication and background noise (nicotine withdrawal inherently causes mood changes, and psychiatric patients inherently have mood fluctuations). A placebo-controlled trial was absolutely required to separate the drug effect from withdrawal symptoms and baseline disease progression.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The EAGLES trial utilized a complex, customized composite endpoint for neuropsychiatric adverse events designed in collaboration with the FDA. What are the methodological strengths and vulnerabilities of constructing a novel composite safety endpoint rather than relying on standard MedDRA hierarchies, and how might this affect the trial's power and type-II error rates for rare events?
Key Response
A broad composite endpoint captures a wide safety net, increasing statistical power to detect any event. However, if the composite is driven by lower-severity, high-frequency events like mild agitation, it could dilute the signal of rare, severe events like completed suicide, potentially risking a Type II error for the most critical individual safety outcomes.
The psychiatric cohort in the EAGLES trial required patients to be clinically stable to participate. As a peer reviewer, how does this inclusion criterion threaten the external validity of the study, and does the blanket claim that varenicline is safe in 'patients with psychiatric disorders' overreach the actual trial population?
Key Response
Editors must look for overgeneralization. The trial excluded patients with active, unstable psychiatric disease or recent substance abuse. Therefore, the safety data strictly applies to stable psychiatric patients, and extrapolating these findings to an acutely psychotic or actively suicidal patient is a significant leap that authors must carefully caveat.
Given the definitive safety and superior efficacy data from the EAGLES trial, how should current clinical practice guidelines formally upgrade the recommendation for varenicline in patients with stable psychiatric comorbidities, and should insurance-driven step-therapy (requiring NRT failure first) be officially opposed by professional societies?
Key Response
Guideline committees evaluate whether new evidence mandates a shift in first-line status. The EAGLES trial provides Level 1a evidence that varenicline is safe and superior to NRT, strongly supporting guidelines (like those from the ATS or ACC) to explicitly recommend varenicline as the uncontested first-line agent, effectively abolishing the clinical justification for NRT step-therapy.
Clinical Landscape
Noteworthy Related Trials
Varenicline vs. Bupropion Trial
Tested
Varenicline 1mg twice daily
Population
Healthy adult smokers
Comparator
Bupropion SR or placebo
Endpoint
Continuous abstinence at weeks 9-12
Maintenance Varenicline Trial in Schizophrenia
Tested
Varenicline maintenance therapy
Population
Smokers with schizophrenia or bipolar disorder
Comparator
Placebo
Endpoint
7-day point prevalence abstinence at 52 weeks
EVITA Trial
Tested
Varenicline
Population
Smokers hospitalized with acute coronary syndrome
Comparator
Placebo
Endpoint
Continuous smoking abstinence at 24 weeks
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis